Search Results

The Randox Laboratories Ltd. Lipoprotein (a) test kit is an in vitro diagnostic reagent for the quantitative determination of Lipoprotein (a) in serum and plasma. The method is an immunoturbidimetric assay in which agglutination occurs due to an antigenantibody reaction between Lp(a) in a sample and anti-Lp(a) antibody adsorbed to latex particles. The agglutination is detected as an absorbance change at 700nm proportional to the concentration of Lp(a) in the sample. Lp(a) determination is intended for use in conjunction with clinical evaluation, patient risk assessment and other lipid tests to evaluate disorders of lipid metabolism and lto assess coronary heart disease in specific populations.

The Randox Laboratories Ltd. Lipoprotein (a) test kit is an in vitro diagnostic reagent for the quantitative determination of Lipoprotein (a) in serum and plasma. The method is an immunoturbidimetric assay in which agglutination occurs due to an antigenantibody reaction between Lp(a) in a sample and anti-Lp(a) antibody adsorbed to latex particles. The agglutination is detected as an absorbance change at 700nm proportional to the concentration of Lp(a) in the sample.

I am sorry, but I cannot fulfill your request to describe the acceptance criteria and study proving device performance based on the provided text. The documents you supplied (a 510(k) clearance letter and an Indications for Use statement) do not contain the specific information needed to answer your questions.

Here's why:

• 510(k) Clearance Letter: This letter from the FDA confirms that the device (Randox Laboratories, Ltd. Lipoprotein (a) test kit) is "substantially equivalent" to legally marketed predicate devices. It allows the manufacturer to market the device but does not detail the specific performance studies, acceptance criteria, or ground truth methodologies that led to this determination. Substantial equivalence is based on comparing the new device to existing ones, not necessarily on new, extensive clinical trials for every clearance.
• Indications for Use: This section describes what the device measures (Lipoprotein (a) quantitatively) and its intended purpose (to evaluate lipid metabolism disorders and assess coronary heart disease risk). It outlines the intended use but provides no performance metrics or study details.

To answer your questions, I would need a different type of document, such as:

• A Clinical Study Report
• A Validation Study Report
• A Performance Characterization Document
• The 510(k) submission document itself (parts of it, specifically performance data sections)

Without such documents, I cannot extract the information required for the table and other detailed questions about acceptance criteria, sample sizes, expert qualifications, etc.

Ask a specific question about this device